Wragge Lawrence Graham & Co
- Company/Commercial (9)
- Corporate (7)
- Banking / Finance (2)
- Construction (2)
- Employment (2)
- Environment (2)
- Healthcare (2)
- Information Technology (2)
- Intellectual Property (2)
- Litigation / Dispute Resolution (2)
- Pensions (2)
- Personal tax / Trusts (2)
- Planning (2)
- Real Estate (2)
- Tax (2)
- Business Tax (1)
- Competition/EU (1)
- Energy (1)
- Funds (1)
- Insolvency & restructuring (1)
- Licensing/Gaming/Betting (1)
- Media/Entertainment/Sport (1)
- PPP/PFI/Commercial projects (1)
- Private Client (1)
- Public Sector/Local Authority (1)
- Telecoms (1)
Sort By: Newest first | Oldest first
Wragge Lawrence Graham & Co’s life sciences experts have advised AstraZeneca on its definitive agreement with Genzyme to divest Caprelsa (vandetanib), a rare disease medicine.
Wragge Lawrence Graham & Co has advised AstraZeneca on a co-development and commercialisation agreement with Innate Pharma SA, a biopharmaceutical company developing therapeutic antibodies for the treatment of cancer.
Wragges has advised long-standing client on a three-year drug discovery collaboration agreement with Orca.
Wragge Lawrence Graham & Co has advised GlaxoSmithKline (GSK) on the sale of its shareholding interests in biopharmaceutical company Convergence Pharmaceuticals to Biogen Idec.
Chambers UK has placed Wragge Lawrence Graham & Co in 43 categories, 17 of which are in Band 1.
According to The Legal 500, following the merger of Wragge & Co and Lawrence Graham in May 2014, the firm has ‘more strength and depth as well as wider international coverage’.
Wragge Lawrence Graham & Co has advised AstraZeneca on its alliance with Lilly to develop and commercialise an Alzheimer’s inhibitor.
Wragge Lawrence Graham & Co has advised biopharmaceutical company arGEN-X on its first collaboration with Bayer and on a strategic alliance with Shire.
Wragge & Co’s life sciences team has brokered a licensing agreement between AstraZeneca and a partnership of Belgian life sciences research institutes.